Combined modality therapy of gemcitabine and radiation - PubMed (original) (raw)
Review
Combined modality therapy of gemcitabine and radiation
Bea Pauwels et al. Oncologist. 2005 Jan.
Free article
Abstract
The combination of gemcitabine and radiotherapy is a promising combined modality therapy. However, the clinical application of this combination has to be implemented carefully because of an increased toxicity to normal tissues. A body of experimental evidence shows that gemcitabine is a potent radiosensitizer in vitro and in vivo. The observations so far indicate that various mechanisms are responsible for the radiosensitizing effect. Although it is often difficult to transfer experimental data to the clinic, these studies offer the possibility to develop an improved schedule of administration for patient treatment, based on rational evidence in tumor biology. In the current review, the preclinical data that support the use of gemcitabine as a radiosensitizing agent and the clinical trials that have been conducted to date are summarized.
Similar articles
- [Concomitant use of radiotherapy and gemcitabine: preclinical findings and clinical practice].
Azria D, Coelho M, Larbouret C, Lemanski C, Serre A, Ychou M, Pèlegrin A, Dubois JB, Culine S. Azria D, et al. Cancer Radiother. 2004 Nov;8 Suppl 1:S106-13. Cancer Radiother. 2004. PMID: 15679255 Review. French. - Radiosensitization by gemcitabine.
Lawrence TS, Eisbruch A, McGinn CJ, Fields MT, Shewach DS. Lawrence TS, et al. Oncology (Williston Park). 1999 Oct;13(10 Suppl 5):55-60. Oncology (Williston Park). 1999. PMID: 10550827 Review. - [Combined gemcitabine and radiotherapy].
Mornex F. Mornex F. Bull Cancer. 2002 Aug;89 Spec No:S127-33. Bull Cancer. 2002. PMID: 12449044 Review. French. - Evolving considerations in the design and interpretation of phase I trials investigating gemcitabine based chemoradiotherapy regimens.
McGinn CJ. McGinn CJ. Cancer J. 2002 May-Jun;8(3):239-41. doi: 10.1097/00130404-200205000-00006. Cancer J. 2002. PMID: 12074322 No abstract available. - Enhancement of tumor radioresponse in vivo by gemcitabine.
Milas L, Fujii T, Hunter N, Elshaikh M, Mason K, Plunkett W, Ang KK, Hittelman W. Milas L, et al. Cancer Res. 1999 Jan 1;59(1):107-14. Cancer Res. 1999. PMID: 9892194
Cited by
- Targeted Therapeutic Strategies for the Treatment of Cancer.
Victoir B, Croix C, Gouilleux F, Prié G. Victoir B, et al. Cancers (Basel). 2024 Jan 22;16(2):461. doi: 10.3390/cancers16020461. Cancers (Basel). 2024. PMID: 38275901 Free PMC article. Review. - Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer: a phase I/II study protocol (TT-LAP trial).
Shimomura O, Endo M, Makishima H, Yamada T, Hashimoto S, Numajiri H, Miyazaki Y, Doi M, Furuya K, Takahashi K, Moriwaki T, Hasegawa N, Yamamoto Y, Niisato Y, Kobayashi M, Mizumoto M, Nakai K, Saito T, Hoshiai S, Saida T, Mathis BJ, Mori K, Nakajima T, Tsuchiya K, Sakurai H, Oda T. Shimomura O, et al. BMC Cancer. 2023 Jul 4;23(1):624. doi: 10.1186/s12885-023-11110-y. BMC Cancer. 2023. PMID: 37403011 Free PMC article. - Berberine enhances the sensitivity of radiotherapy in ovarian cancer cell line (SKOV-3).
Aleissa MS, Al-Zharani M, Alneghery LM, Aleissa AM. Aleissa MS, et al. Saudi Pharm J. 2023 Jan;31(1):110-118. doi: 10.1016/j.jsps.2022.11.009. Epub 2022 Nov 15. Saudi Pharm J. 2023. PMID: 36685297 Free PMC article. - Bcl-xL inhibition radiosensitizes PIK3CA/PTEN wild-type triple negative breast cancers with low Mcl-1 expression.
Pesch AM, Chandler BC, Michmerhuizen AR, Carter HM, Hirsh NH, Wilder-Romans K, Liu M, Ward T, Ritter CL, Nino CA, Jungles KM, Pierce LJ, Rae JM, Speers CW. Pesch AM, et al. Cancer Res Commun. 2022 Jul;2(7):679-693. doi: 10.1158/2767-9764.crc-22-0024. Epub 2022 Jul 20. Cancer Res Commun. 2022. PMID: 36381235 Free PMC article. - The use of radiosensitizing agents in the therapy of glioblastoma multiforme-a comprehensive review.
Pepper NB, Stummer W, Eich HT. Pepper NB, et al. Strahlenther Onkol. 2022 Jun;198(6):507-526. doi: 10.1007/s00066-022-01942-1. Epub 2022 May 3. Strahlenther Onkol. 2022. PMID: 35503461 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources